Evidence map›Paper›PMID 20160123›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2010

Prostaglandin F2alpha represses IGF-I-stimulated IRS1/phosphatidylinositol-3-kinase/AKT signaling in the corpus luteum: role of ERK and P70 ribosomal S6 kinase.

Edward Arvisais, Xiaoying Hou, Todd A Wyatt, Koumei Shirasuna, Heinrich Bollwein, Akio Miyamoto, Thomas R Hansen, Bo R Rueda, John S Davis

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The roles of prostaglandin FSignal transduction and targeted therapy
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Edward ArvisaisOmaha Veterans Affairs Medical Center, Omaha, Nebraska 68105, USA.
Xiaoying Hou
Todd A Wyatt
Koumei Shirasuna
Heinrich Bollwein
Akio Miyamoto
Thomas R Hansen
Bo R Rueda
John S Davis
Veterans Health Administration · USObihiro University of Agriculture and Veterinary Medicine · JPColorado State University · USMassachusetts General Hospital · USUniversity of Veterinary Medicine Hannover, Foundation · DE

Funding

Airway Injury Caused by MAA AdductsR01AA017993 · NIAAA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WYATT, TODD A · 2008 to 2012
$1.9M
Preventing bar violence: New directions from theory-based multi-level analysesR01AA017663 · NIAAA · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI GRAHAM, KATHRYN MARIE, OSGOOD, D WAYNE · 2009 to 2011
$756k
Role of Egr-1 in Corpus Luteum FunctionR03HD048754 · NICHD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DAVIS, JOHN S · 2005 to 2006
$145k
NIAAA NIH HHS AA017663NIAAA NIH HHS R01 AA017663NIAAA NIH HHS R01 AA017993NICHD NIH HHS HD048754NICHD NIH HHS R03 HD048754
6 · The paper itself

Abstract

Little is known about the early intracellular events that contribute to corpus luteum regression. Experiments were designed to determine the effects of prostaglandin F2alpha (PGF2alpha) on phosphatidylinositol-3-kinase (PI3K)/Akt signaling in the corpus luteum in vivo and in vitro. Treatment of midluteal-phase cows with a luteolytic dose of PGF2alpha resulted in a rapid increase in ERK and mammalian target of rapamycin (mTOR)/p70 ribosomal protein S6 kinase (p70S6K1) signaling and a rapid suppression of Akt phosphorylation in luteal tissue. In vitro treatment of primary cultures of luteal cells with PGF2alpha also resulted in an increase in ERK and mTOR/p70S6K1 signaling and a diminished capacity of IGF-I to stimulate PI3K, Akt, and protein kinase C zeta activation. Accounting for the reductions in PI3K and Akt activation observed in response to PGF2alpha treatment, we found that PGF2alpha promoted the phosphorylation of serine residues (307, 612, 636) in the insulin receptor substrate 1 (IRS1) peptide sequence in vivo and in vitro. Serine phosphorylation of IRS1 was associated with reduced formation of IGF-I-stimulated IRS1/PI3Kp85 complexes. Furthermore, treatment with inhibitors of the MAPK kinase 1/ERK or mTOR/p70S6K1 signaling pathways prevented PGF2alpha-induced serine phosphorylation of IRS1 and abrogated the inhibitory actions of PGF2alpha on Akt activation. Taken together, these experiments provide compelling evidence that PGF2alpha treatment stimulates IRS1 serine phosphorylation, which may contribute to a diminished capacity to respond to IGF-I. It seems likely that the rapid changes in phosphorylation events are among the early events that mediate PGF2alpha-induced corpus luteum regression.

Indexed as

AnimalsBlotting, WesternCattleCells, CulturedCorpus LuteumDinoprostEnzyme ActivationFemaleInsulin-Like Growth Factor IInsulin Receptor Substrate ProteinsIntracellular Signaling Peptides and ProteinsPhosphatidylinositol 3-KinasesPhosphorylationProtein Kinase CProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktDinoprostInsulin-Like Growth Factor IInsulin Receptor Substrate ProteinsIntracellular Signaling Peptides and ProteinsPhosphatidylinositol 3-KinasesProtein Kinase CProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktReceptor, IGF Type 1Ribosomal Protein S6 Kinases, 70-kDaTOR Serine-Threonine Kinases

Identifiers

PMID20160123
PMCPMC2840803
OpenAlexW2076058495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.